ClinicalTrials.gg
CompletedNCT02879084Updated Jan 27, 2021

Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis

An observational study in Anterior Uveitis and Intermediate Uveitis, sponsored by CHU de Quebec-Universite Laval. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-27.

Sponsored by CHU de Quebec-Universite Laval · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
36
Ages
18 Years and older
Sex
All
01

Study summary

This study investigates the variations in the retinal nerve fiber layer (RNFL) thickness during uncomplicated anterior and intermediate uveitis, respectively. The objectives are to 1 ) confirm the RNFL thickening during an uncomplicated anterior uveitis as described in the literature, 2) measure the RNFL thickness during an uncomplicated intermediate uveitis specifically and 3) describe the variation in time of RNFL thickness during the two types of uveitis.

Read the detailed description

Thirty six individuals (18 with anterior uveitis and 18 with intermediate uveitis) will be recruited at the Centre universitaire d'ophtalmologie du CHU de Québec. RNFL thickness will be measured with optical coherence tomography at 3 times. For anterior uveitis, the RNFL thickness will be measured at presentation, 1 week and 4 to 6 weeks. For intermediate uveitis, the RNFL thickness will be measured at presentation, 4 to 6 weeks and 4 months. The initial thickness will be studied for each type of uveitis and progression over time will be studied also for each type of uveitis.

02

Conditions studied

  • Anterior Uveitis
  • Intermediate Uveitis
03

In context

Uveitis, Anterior

56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.

This study's enrollment of 36 is below the median of 77 across 10 observational studies indexed under Uveitis, Anterior.

Browse Uveitis, Anterior studies →

Lead sponsor

CHU de Quebec-Universite Laval is the lead sponsor of 137 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult of 18 years old or more with anterior or intermediate uncomplicated uveitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old or more
  • anterior uncomplicated uveitis or intermediate uncomplicated uveitis

Exclusion criteria

Exclusion Criteria:

  • history of uveitis in the past, other than the actual uveitis
  • history of ophthalmologic pathology with potential impact on retinal nerve fiber layer thickness
  • optic nerve or macular clinically apparent edema
  • history of glaucoma or other optic neuropathy
  • suspected or confirmed multiple sclerosis
  • ocular hypertension (intraocular pressure more than 22 mmHg)
  • reduced optical coherence tomography signal (lower than 7) on the Cirrus HD-OCT
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
36 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Retinal Nerve Fiber Layer Thickness in anterior uveitis

    Time frame: At time 0

  2. Retinal Nerve Fiber Layer Thickness in intermediate uveitis

    Time frame: At time 0

  3. Change from Baseline Retinal Nerve Fiber Layer Thickness in anterior uveitis

    Time frame: at 4 to 6 weeks

  4. Change from Baseline Retinal Nerve Fiber Layer Thickness in intermediate uveitis

    Time frame: at 4 months

07

Study locations

1 site
  • Centre universitaire d'ophtalmologie, Hôpital du Saint-Sacrement. CHU de Québec
    Québec, G1S 4LB, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Dec 2020, 52 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2016
First posted
Aug 25, 2016
StartActual
Aug 2016
Primary completionActual
Dec 2020
CompletionActual
Dec 2020
Last update
Jan 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02879084
Responsible party
Sponsor
First posted
Aug 25, 2016
Start date
Aug 2016
Primary completion
Dec 2020
Completion
Dec 2020
Last update
Jan 27, 2021

Study contacts

Simon Couture, Doctor
principal investigator · Centre de recherche du CHU de Québec : Université Laval

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion